Risk of product supply delays due to manufacturing facilities and raw materials
First written in FY2017. 8 of 10 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 3 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If product supplies are delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, or if products must be recalled or other measures taken due to quality problems, this could materially affect the operating results and financial position of our group.」
The risks of supply delays and product recalls due to problems involving manufacturing facilities, raw materials and quality continue to be disclosed. - FY2022RestatedAnnual report
「If product supplies are delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, or if products must be recalled or other measures taken due to quality problems,」
The risks of supply delays and product recalls due to equipment malfunctions at our own facilities or suppliers' facilities, delays in obtaining raw materials and quality problems continue to be disclosed. Meanwhile, the main text explains that stable supplies are being maintained through cooperation with business partners. - FY2022-Q3RestatedAnnual report
「We have maintained stable supplies in cooperation with our business partners, and as of now no situation has arisen that would disrupt the production of our pharmaceuticals or their supply to medical institutions.」
The explanation that cooperation with business partners has prevented disruptions to production or the supply of pharmaceuticals to medical institutions continues, even amid the spread of COVID-19. - FY2022-Q2RestatedAnnual report
「We have maintained stable supplies in cooperation with our business partners, and as of now no situation has arisen that would disrupt the production of our pharmaceuticals or their supply to medical institutions.」
The explanation that cooperation with business partners has prevented disruptions to the production of pharmaceuticals or their supply to medical institutions continues, even amid the spread of infectious diseases. - FY2021RestatedAnnual report
「If product supplies are delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, or if products must be recalled or other measures taken due to quality problems」
In addition to problems involving manufacturing facilities and raw materials, product recalls due to quality problems were explicitly identified as a supply risk. Meanwhile, the main text explains that stable supplies are being maintained through cooperation with business partners. - FY2021-Q2RestatedAnnual report
「We have maintained stable supplies in cooperation with our business partners, and as of now no situation has arisen that would disrupt the production of our pharmaceuticals or their supply to medical institutions.」
The explanation that cooperation with business partners has prevented disruptions to the production and supply of pharmaceuticals continues, even amid the spread of COVID-19. - FY2021-Q1MitigatedAnnual report
「We have maintained stable supplies in cooperation with our business partners, and as of now no situation has arisen that would disrupt the production of our pharmaceuticals or their supply to medical institutions.」
It is explained that, even amid the spread of COVID-19, cooperation with business partners has prevented disruptions to the production and supply of pharmaceuticals. - FY2019RestatedAnnual report
「Product supplies may be delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, which could affect business performance.」
The risk of product supply disruptions due to equipment malfunctions at our own facilities or suppliers' facilities and delays in obtaining raw materials continues to be disclosed. - FY2018RestatedAnnual report
「Product supplies may be delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, which could affect business performance.」
The supply risk arising from equipment malfunctions at our own facilities or suppliers' facilities and delays in obtaining raw materials continues to be disclosed. - FY2017First statedAnnual report
「Product supplies may be delayed or suspended due to malfunctions at our own or suppliers' manufacturing facilities, delays in obtaining raw materials or other factors, which could affect business performance.」
The possibility of supply delays or suspensions due to equipment malfunctions at our own facilities or suppliers' facilities and delays in obtaining raw materials is disclosed.